NEW YORK, NY--(Marketwire -07\/18\/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 37 percent and 35 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Lexicon Pharmaceuticals, Inc. (LXRX) and Rosetta Genomics Ltd. (ROSG). <\/p>\n
Access to the full company reports can be found at: http:\/\/www.ParagonReport.com\/LXRX<\/a> http:\/\/www.ParagonReport.com\/ROSG<\/a> <\/p>\n Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is \"so high that prices are more easily accepted by the regulators.\" <\/p>\n Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http:\/\/www.ParagonReport.com<\/a> and get exclusive access to our numerous stock reports and industry newsletters. <\/p>\n Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has five drug programs in mid-stage development for diabetes, carcinoid syndrome, irritable bowel syndrome, rheumatoid arthritis and glaucoma, all of which were discovered by Lexicon's research team. Shares of the company are up over 140 percent year-to-date. <\/p>\n Rosetta Genomics is a leading developer of microRNA-based diagnostic tests and therapeutic tools. MicroRNAs are a recently discovered group of short, non-coding genes which regulate the expression of other genes. MicroRNA-based diagnostics may offer physicians and patients an objective tool to accurately identify cancer, predict outcomes and help guide treatment. <\/p>\n The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http:\/\/www.paragonreport.com\/disclaimer<\/a> <\/p>\n<\/p>\n Excerpt from: NEW YORK, NY--(Marketwire -07\/18\/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 37 percent and 35 percent, respectively, outperforming the broader market by a wide margin Continue reading
\nLexicon Pharmaceuticals and Rosetta Genomics Showing Impressive Growth in 2012<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"